US FDA Grants Expanded Approval of ELEVIDYS Gene Therapy for DMD Patients Ages 4 and Above

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Overview of Preexisting Antibody Testing Prior to AAV Gene Therapy presented by Sarepta Therapeutics

Activity Snapshot

Release Date: 
Wednesday, July 19, 2023
Expiration Date: 
Wednesday, July 26, 2023
Screenshot of webinar
Activity Overview: 

Testing to assess preexisting antibodies to the delivery vector (i.e., AAV) is one of the important factors in determining eligibility for gene therapies. Join us to learn more about antibody testing including AAV serotypes, antibody-mediated immunologic responses, testing methodologies (Total binding vs Neutralizing), titers, seroprevalence rates and a Sarepta-sponsored testing program to detect pre-existing total binding antibodies to the AAVrh74 vector.